RxDoctor Payments Data

Tiffany Son

Surgery · Tucson, AZNPI 1114373388

Payments from drug & device makers

What this record shows

This record is dominated by education: $30,510 of the $47,019 with a category attached, or 64.9%. Intuitive Surgical accounts for 86.5% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $18,140, more than ten times the $32 reported in 2019. Among surgery clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,019in general payments, 2019–2025

Across 186 payments — averaging $252.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$41K
  • Davol Inc.$3K
  • Medtronic$1K
  • Phathom Pharmaceuticals, Inc.$1K
  • Novo Nordisk$299
  • Trimed, Inc.$142
  • plus $598 from 10 others

What the payments were for

  • Speaking & faculty fees$1,5753%
  • Travel & lodging$5,48912%
  • Food & beverage$9,39520%
  • Education$30,51065%
  • Gifts$500%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,019 in reported general payments places this provider in the 90th percentile of 614 surgery providers in Arizona.

See all surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$65,612
Medicare patients
142
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$86,293
MounjaroTirzepatide40$43,592
TrulicityDulaglutide32$31,682
WegovySemaglutide14$19,197
Omeprazole20$295
Ondansetron Hcl21$261
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen42$216
Nystatin12$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$299$105,48999 claims
Lilly USA, LLCMounjaro, Trulicity$25$75,27472 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 surgery providers in Arizona.

Other surgery in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →